You are here: Industry Insights > Boehringer Ingelheim

News List

Boehringer Ingelheim expands collaboration with Vanderbilt University to tackle some of the most dif worldpharmanews
March 09, 2017
Boehringer Ingelheim has announced a new collaboration with Vanderbilt University, Nashville, Tennessee.
Boehringer Ingelheim and Sanofi close business swap in India expressbpd
March 02, 2017
Globally, both companies will become leaders in two different sectors of the pharmaceutical market
Boehringer Ingelheim and Weill Cornell Medicine announce new collaboration biospectrumasia
February 21, 2017
To identify novel treatment approaches that could halt or even reverse lung tissue damage in COPD
FDA expands approval of Spiriva Respimat inhalation spray cphi-online
February 20, 2017
Steroid-free Spiriva Respimat now approved as asthma treatment for age 6 and older.
Boehringer Ingelheim and Weill Cornell Medicine announce new collaboration to discover next generati firstwordpharma
February 16, 2017
Boehringer Ingelheim today announced a collaboration with Weill Cornell Medicine to identify new treatment approaches for chronic obstructive pulmonary disease (COPD)...
Boehringer Ingelheim to Evaluate Afatinib in Combination with PD-1 Inhibitor Pembrolizumab in New Tr americanpharmaceuticalreview
February 10, 2017
Boehringer Ingelheim has announced the initiation of a Phase II trial of afatinib (Gilotrif®) in combination with pembrolizumab (Keytruda®) for patients with locally advanced or metastatic squamous cell carcinoma (SqCC) of the lung.
Boehringer Ingelheim Biosimilar Candidate to Humira® Accepted for EMA and FDA Regulatory Review americanpharmaceuticalreview
January 20, 2017
Boehringer Ingelheim announced that BI 695501, its adalimumab biosimilar candidate to Humira®, has been accepted for regulatory review by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page